This website uses cookies, including third party ones, to allow for analysis of how people use our website in order to improve your experience and our services. By continuing to use our website, you agree to the use of such cookies. Click here for more information on our and .
Life Science Incubator (LSI) isn’t trying to reinvent the wheel — it’s simply making it roll faster. By creating accessible, scalable lab infrastructure and embedding it within a supportive community, LSI is helping to fast-track the next generation of biotech and medtech solutions, from idea to impact.
As the Asia-Pacific region doubles down on innovation, models like LSI may well become the new standard, not just for where science is done, but how it’s brought to life.
Ahead of Informa Australia’s life sciences trade mission to Singapore, we took a closer look at one of the key partners we will be visiting during our Singapore visit.
In Singapore’s rapidly evolving biotech and medtech landscape, LSI is quietly redefining how early-stage innovation takes root. Built on a simple but powerful idea — that access to lab space shouldn’t be a barrier to progress — LSI provides fully fitted, co-working laboratories tailored to the needs of life science startups. This ready-to-go environment allows researchers and entrepreneurs to focus on science from day one, bypassing the traditional infrastructure hurdles that can slow momentum.
“Our mission is to enable early-stage life sciences innovation by providing access to critical infrastructure, shared equipment, and a supportive community,” says LSI.
It’s a model that fits seamlessly into Singapore’s broader vision to become a regional powerhouse for translational research and commercialisation. With its strong policy support, global talent attraction, and emphasis on innovation, Singapore is fostering an ecosystem where early-stage biotech and medtech companies can thrive. LSI plays a critical role in this ecosystem by not only offering space and equipment but also cultivating a collaborative community that encourages knowledge exchange and cross-disciplinary interaction.
That sense of community has already helped launch a number of notable ventures. Among them is Cuprina, a startup pioneering maggot debridement therapy for wound care. Starting within LSI’s lab space, Cuprina has since scaled into its own facility. Another standout is Avecris, which is developing virus-like particles for gene delivery — a technology with significant implications for the future of gene therapies. These companies exemplify the kind of high-potential, early-stage science that LSI is designed to support.
According to LSI, “These companies are perfect examples of the transformative work happening in our labs,” LSI shares. “It’s incredibly rewarding to support them during these critical early stages.”
LSI’s own growth reflects the increasing demand for agile lab infrastructure. What began as a single site in Singapore has now expanded to two, and the incubator recently announced its first international expansion, choosing Brisbane as the gateway into Australia. The choice was a strategic one. With Australia’s robust research and clinical trial ecosystem and Singapore’s strengths in commercialisation and access to Asian markets, there is clear potential for cross-border collaboration. Areas such as diagnostics, medtech, and digital health stand to benefit most from this regional connectivity.
Emerging technologies in cell and gene therapy, AI-powered diagnostics, and personalised medicine are creating new opportunities for startups in the region. Digital health, too, is gaining momentum, particularly in remote monitoring and predictive analytics — areas where Singapore’s integrated health systems and digital infrastructure provide a strong foundation.
By removing friction from the earliest stages of innovation and providing the flexibility needed to scale, LSI is building more than labs — it’s building bridges. Between science and business, between countries, and between the promise of an idea and the reality of its impact. In doing so, it’s helping shape the future of biotech in Asia, one experiment at a time.
Learn more about LSI and the APAC Biotech landscape by joining the Informa Life Sciences Trade Mission to Singapore. Full details at www.informatrademissions.com.au
Images courtesy of LSI
